Innovent Biologics, Inc. · HKEX:1801
Innovent Biologics — FY2019 Earnings Presentation
38 slides from Innovent Biologics's earnings presentation, March 2020
Slide 1: 2019 Annual Results Presentation
2019 Annual Results Presentation March 2020 To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people Confidential Copyright© 2020 Innovent Biologics 0
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our bu
Slide 3: Our Mission, Vision and Development Strategy
Our Mission, Vision and Development Strategy COMPANY MISSION COMPANY VISION COMPANY STRATEGY To develop and commercialize high To be the premier biopharmaceutical Robust and high quality pipeline quality biopharmaceuticals that are company in China Global standard cGMP biologics affordable to ordina
Slide 4: Our History
Our History Tyvyt® (sintilimab injection) listed in the NRDL Granted priority review status for the NDAs of three biosimilars (IBI-301, IBI-303 and IBI-305) by the NMPA Strategic partnership with Eli Lilly for diabetes Tyvyt® (sintilimab injection) included in the 2019 guidelines of the CSCO
Slide 5: Major Accomplishments since 2019 to March 2020
Major Accomplishments since 2019 to March 2020 EXPANDED STRATEGIC PARTNERSHIP WITH ELI LILY AND COMPANY • License in mid-stage potentially global best-in-class diabetes molecule product candidate • IND application of the molecule accepted by the NMPA 1st LAUNCH WITH STRONG MOMENTUM - TYVYT® (SINTILI
Slide 6: Agenda
Agenda 1 COMMERCIALIZATION OF TYVYT® (SINTILIMAB INJECTION) 2 Research & Development 3 Manufacturing Facilities 4 Global Partnerships 5 Organization & Fundraise 6 Financial Review 7 Outlook Copyright© 2020 Innovent Biologics 5
Slide 7: Commercialization Summary of 2019
Commercialization Summary of 2019 Delivered strong sales Established competitive brand perception results with sound in medical society with high quality KOL counter-competitive campaign engagement and SOV campaigns STRENGTHEN SUCCESSFUL COMMERCIAL NRDL CAPABILITY STRONG SALES ESTABLISHED BRAND PERF
Slide 8: Commercialization of Tyvyt (Sintilimab Injection)
Commercialization of Tyvyt® (Sintilimab Injection) Flawless Execution Led to Solid Results in 2019 March 9, 2019 2019 SALES LAUNCHED Sales reached Tyvyt® (sintilimab injection) RMB1,015.9 Million Copyright© 2020 Innovent Biologics 7
Slide 9: Commercialization of Tyvyt (Sintilimab Injection)
Commercialization of Tyvyt® (Sintilimab Injection) Flawless Execution Led to Solid Results in 2019 Tyvyt® (sintilimab injection) is the ONLY PD-1 inhibitor listed in the NRDL Demonstrated its clinical value recognition from NHSA and increased affordability and accessibility for patients Copyrigh
Slide 10: Established Competitive Brand Perception with High Quality KOL Engagement
Established Competitive Brand Perception with High Quality KOL Engagement InnOncology Online Medical Consultation Innoventbio Oncology Form covered the Top KOL in China, including 3 academician Free medical consultation in work with 3rd party to engage KOL at online platform KOL interview after Prom
Slide 11: Established Broad and Deep Commercial Footprint throughout China
Established Broad and Deep Commercial Footprint throughout China 30 ~300 ~2,000 ~500 ~700 Provinces Cities Target DTP/ Commercial Coverage Coverage Hospital Pharmacies Team Size Copyright© 2020 Innovent Biologics 10
Slide 12: Built a Competitive and Professional Commercial Force
Built a Competitive and Professional Commercial Force AUTO-IMMUNE BU & COO SALES SOUTH CHINA SALES NORTH CHINA MARKETING CHANNEL MANAGEMENT MIN LIU KEWIN XU DONGSHENG LIU SPARKLER MAO LI CHEN Chief Commercial Officer, General Manager of Innovent Shanghai Branch • East 1 • North • Medical Marketing •
Slide 13: Agenda
Agenda 1 Commercialization of Tyvyt® (Sintilimab Injection) 2 RESEARCH & DEVELOPMENT 3 Manufacturing Facilities 4 Global Partnerships 5 Organization & Fundraise 6 Financial Review 7 Outlook Copyright© 2020 Innovent Biologics 12
Slide 14: Select Robust Pipeline Across Novel Therapeutics
Select Robust Pipeline Across Novel Therapeutics Status (China) IND Products Target (s) Therapeutic Area Commercial Rights Pre-clinical Phase1 Phase 2 Phase 3 NDA Launched Filed Accepted sintilimab (IBI-308) PD-1 Oncology Worldwide NDA approved: Dec 24, 2018 * IBI-303 (adalimumab biosimilar) TNF-alp
Slide 15: Robust R&D Platforms and Oncology Product Candidates
Robust R&D Platforms and Oncology Product Candidates IBI-318 (PD-1/ PD-L1) IBI-308 (PD-1) IBI-188 (CD47) IBI-315（PD-1/HER2） IBI-301 (CD20) IBI-101 (OX40) IBI-322 (PD-L1/ CD47) IBI-305 (VEGF-A) IBI-110 (LAG-3) IBI-323 (LAG-3/PD-L1) IBI-310 (CTLA-4) IBI-939 (TIGIT) IBI-319 (PD-1/unspecified) IBI-375 (
Slide 16: Clinical Development Programs for Tyvyt (Sintilimab Injection)
Clinical Development Programs for Tyvyt® (Sintilimab Injection) 27 Studies with 12 Registratinal or Pivotal Trials Ongoing or under Planning STATUS PHASE 1 NDA INDICATION MONO-/COMBO-THERAPY (OTHER COMPONENTS) 1A 1B PHASE 2 PHASE 3 NDA FILED APPROVED China r/r Classical Hodgkin’s Lymphoma Mono 1L No
Slide 17: Clinical Development Programs for Tyvyt (Sintilimab Injection)
Clinical Development Programs for Tyvyt® (Sintilimab Injection) 27 Studies with 12 Registratinal or Pivotal Trials Ongoing or under Planning STATUS PHASE 1 NDA INDICATION MONO-/COMBO-THERAPY (OTHER COMPONENTS) 1A 1B PHASE 2 PHASE 3 NDA FILED APPROVED China 1L Squamous NSCLC Combo (gemcitabine and ci
Slide 18: Clinical Highlights of Tyvyt and IBI-303
Clinical Highlights of Tyvyt® (Sintilimab Injection) and IBI-303 (Biosimilar to Adalimumab) Cover Story of Tyvyt® (sintilimab) Published at Inaugural Issue of at The Lancet Haematology The Lancet Rheumatology Pivotal trials in patients with Equivalence trial between relapsed or refractory classical
Slide 19: Agenda
Agenda 1 Commercialization of Tyvyt® (Sintilimab Injection) 2 Research & Development 3 MANUFACTURING FACILITIES 4 Global Partnerships 5 Organization & Fundraise 6 Financial Review 7 Outlook Copyright© 2020 Innovent Biologics 18
Slide 20: State-of-the-art Manufacturing Facilities Designed, Built and Operated at International Standards
State-of-the-art Manufacturing Facilities Designed, Built and Operated at International Standards with Large Scale TOTAL CAPACITY IN THE FUTURE: 83,000 L Designed for FDA, EMA and NMPA standards and support the full Manufacturing team with 4 x 15,000 L Planned process from DS to DP. DS, DP and exten
Slide 21: Agenda
Agenda 1 Commercialization of Tyvyt® (Sintilimab Injection) 2 Research & Development 3 Manufacturing Facilities 4 GLOBAL PARTNERSHIPS 5 Organization & Fundraise 6 Financial Review 7 Outlook Copyright© 2020 Innovent Biologics 20
Slide 22: Striving to Be the Partner of Choice
Striving to Be the Partner of Choice Strategic Partnerships with Renowned Global Partners Mar 20th, 2015 Dec 17th, 2018 • Innovent licensed out PD-1 mAb ex-China to Lilly • Innovent licensed in 3 clinical-stage molecules • Co-development of 3 mAbs in China • Transformed Innovent from only a focus on
Slide 23: Expanded Collaboration with Eli Lilly
Expanded Collaboration with Eli Lilly • Licensed in a mid-stage potentially global best-in-class diabetes molecule for China development and commercialization 1 Expanded efforts in metabolic diseases into the diabetes area OXM3 • Licensed out ex-China right of additional 3 PD-1 bispecific mAbs to
Slide 24: Agenda
Agenda 1 Commercialization of Tyvyt® (Sintilimab Injection) 2 Research & Development 3 Manufacturing Facilities 4 Global Partnerships 5 ORGANIZATION & FUNDRAISE 6 Financial Review 7 Outlook Copyright© 2020 Innovent Biologics 23
Slide 25: Expanded All-Rounded Talent Team
Expanded All-Rounded Talent Team ~2,000 employees Commercialization Team R&D Team CMC Team General and Administrative Team 700 employees Fully fledged team in sales, medical affairs, 700+ employees 500 employees 100+ employees strategy planning and operation functions Copyright© 2020 Innovent Biolog
Slide 26: Executives with a Proven Track Record of Success
Executives with a Proven Track Record of Success Visionary Founder, Chairman and CEO Supported by Experienced Management Team Dr. MICHAEL YU Dr. QINWEI ZHOU RONNIE EDE MIN LIU VIVIAN ZHANG Founder, Chairman & CEO Chief Operating Officer Chief Financial Officer Chief Commercial Officer, Chief People
Slide 27: Senior Management Team with a Proven Track Record of Success
Senior Management Team with a Proven Track Record of Success Visionary Founder, CEO and Chairman Supported by Experienced Management Team Zane Yang Amy Que Wei Xu Junjian Liu Wei Xu SVP SVP SVP VP VP General Manager Quality (QC & QA) Biologics Discovery Translational Manufacturing Innovent Biologics
Slide 28: Strong Support from Globally Renowned Investors
Strong Support from Globally Renowned Investors US$485M IPO & Over US$1.7B in aggregate Cornerstone US$304M The largest IPO fund raise at the time for pre- Follow-On Offering (October 2019) revenue biopharmaceutical company US$303M Over US$600M follow-on offering Follow-On Offering (February 2020) T
Slide 29: Recognitions by the Investment Communities
Recognitions by the Investment Communities ASIA-PACIFIC HONG KONG EQUITY IPO OF THE YEAR ISSUE OF THE YEAR Awarded by CHIC (China Healthcare Investment Conference) the “IPO of the year 2018” A component of the MSCI China Included in the Hang Seng Hong Kong-Listed Biotech Index Copyright© 2020 Innove
Slide 30: Agenda
Agenda 1 Commercialization of Tyvyt® (Sintilimab Injection) 2 Research & Development 3 Manufacturing Facilities 4 Global Partnerships 5 Organization & Fundraise 6 FINANCIAL REVIEW 7 Outlook Copyright© 2020 Innovent Biologics 29
Slide 31: Income Statement
Income Statement IFRS Measure Year ended 31 December RMB'million 2019 2018 Revenue 1,047.5 9.5 Cost of sales (124.9) - Revenue Gross profit (IFRS Measure) 922.6 9.5 In 2019, we generated revenue of RMB1,047.5 million, including RMB1,015.9 million driven by product sales of Other income 144.1 93.8
Slide 32: Income Statement (Non-IFRS Measure)
Income Statement Non-IFRS Measure Year ended 31 December RMB'million 2019 2018 Revenue 1,047.5 9.5 Cost of sales (113.4) - Gross profit (IFRS Measure) 934.1 9.5 Other income 144.1 93.8 Research and development expenses (1,260.7) (1,204.3) Selling and marketing expenses -Direct selling and marketing
Slide 33: Balance Sheet
Balance Sheet Year ended 31 December RMB'million 2019 2018 Cash balance Bank balances and cash 4,232.6 4,525.4 Other financial assets 462.6 - As of December 31, 2019, our total Trade receivables 247.9 - cash increased to RMB4,695.2 million Contract assets 2.2 7.5 Other receivables 151.6 73.6 Inven
Slide 34: Agenda
Agenda 1 Commercialization of Tyvyt® (Sintilimab Injection) 2 Research & Development 3 Manufacturing Facilities 4 Global Partnerships 5 Organization & Fundraise 6 Financial Review 7 OUTLOOK Copyright© 2020 Innovent Biologics 33
Slide 35: Key Upcoming Milestones and Catalysts
Key Upcoming Milestones and Catalysts 2020 to Early 2021 01 02 03 04 SALES COMMERCAL CLINICAL CORPORATE GROWTH LAUNCHES ADVANCEMENT DEVELOPMENT • Continue to drive Tyvyt® growth and • Launch IBI-303 (biosimilar to • Receive 3 NDA approvals: for IBI-303 and IBI- • Further expand manufacturing achieve
Slide 36: Expected Multiple Studies Advancement with Continuous Execution
Expected Multiple Studies Advancement with Continuous Execution 2020 to Early 2021 4* 5 Clinical Trials 23 Launch 57+ 13 NDA 27 Phase 3 28 Phase 2 Phase 1 Clinical Sites * Tyvyt approved in Dec 2018, plus three NDA IND approvals expected in 2020 or early 2021 230+ 301 303 305 Patients in Studies Tyv
Slide 37: Innovent: a Leading Platform Company
Innovent: a Leading Platform Company CMC (Manufacturing & Quality) Clinical Development Discovery Commercialization Fully-integrated, Multi-function Platform with World-class Discovery, Development, Manufacturing and Commercialization Capabilities Copyright© 2020 Innovent Biologics 36
Slide 38: Copyright© 2020 Innovent Biologics
Copyright© 2020 Innovent Biologics 37